<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="116043">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01972568</url>
  </required_header>
  <id_info>
    <org_study_id>700461-023</org_study_id>
    <secondary_id>2013-002773-21</secondary_id>
    <nct_id>NCT01972568</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus</brief_title>
  <acronym>ADDRESS II</acronym>
  <official_title>A Phase IIb, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMD Serono</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMD Serono</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>European Union: European Medicines Agency</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, double-blind, randomized, Phase 2b trial to evaluate the efficacy of
      atacicept in subjects with systemic lupus erythematosus (SLE).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of subjects with SLE responder index (SRI) response at Week 24 compared to screening</measure>
    <time_frame>Screening and Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects at Week 24 whose prednisone-equivalent corticosteroid dose has reduced from Screening by &gt;= 25 percent and to a dose of =&lt; 7.5 milligram per day (mg/day), and have no BILAG A or 2B flare in disease activity during Weeks 16 to 24</measure>
    <time_frame>Screening and Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects in the patient global impression of change (PGIC) categories at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from screening visit to Week 24 in prednisone-equivalent corticosteroid (CS) daily dose</measure>
    <time_frame>Screening and Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first SRI response during the treatment period</measure>
    <time_frame>24 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects responding to treatment according to British Isles Lupus Assessment Group (BILAG)-based Combined Lupus Assessment (BICLA)</measure>
    <time_frame>Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Day 1 in medical outcomes study 36-item short form health survey (SF-36)-physical component summary (PCS) and mental component summary (MCS)</measure>
    <time_frame>Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events (AEs)</measure>
    <time_frame>Screening up to 48 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">279</enrollment>
  <condition>Lupus Erythematosus, Systemic</condition>
  <arm_group>
    <arm_group_label>Atacicept 75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Atacicept 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atacicept 75 milligram (mg)</intervention_name>
    <description>Atacicept 75 mg will be administered as subcutaneous injection once weekly for 24 weeks.</description>
    <arm_group_label>Atacicept 75 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atacicept 150 mg</intervention_name>
    <description>Atacicept 150 mg will be administered as subcutaneous injection once weekly for 24 weeks.</description>
    <arm_group_label>Atacicept 150 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matched to atacicept will be administered as subcutaneous injection once weekly for 24 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eligible male and female subjects, aged 18 years or older

          -  Must have at least moderately active SLE, as defined as SLE Disease Activity
             Index-2000  (SLEDAI-2K) score greater than or equal to [&gt;=] 6 at screening visit

          -  At least 4 of the 11 American college of rheumatology (ACR) classification criteria
             for SLE (diagnosed &gt;= 6 months prior to the screening visit)

          -  Be seropositive for anti-nuclear antibodies (ANA) and/or anti-double-stranded
             deoxyribonucleic acid (anti-dsDNA) antibodies

          -  Other protocol defined inclusion criteria could apply

        Exclusion Criteria:

          -  Subjects have demyelinating disorder

          -  Severe central nervous system SLE

          -  Use of cyclophosphamide within 3 months of the screening visit

          -  Urine protein:creatinine ratio (UPCr) &gt;= 2 milligram per milligram (mg/mg) per day

          -  Other protocol defined exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>EMD Serono, Inc., Rockland MA, a subsidiary of Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US Medical Information</last_name>
    <phone>888-275-7376</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Merck KGaA Communication Center</last_name>
    <phone>+49 6151 72 5200</phone>
    <email>service@merckgroup.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Please Contact U.S. Medical Information Located in</name>
      <address>
        <city>Rockland</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>for US Recruiting Sites</last_name>
      <phone>888-275-7376</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Please Contact the Merck KGaA Communication Center Located in</name>
      <address>
        <city>Darmstadt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>for EU Recruiting Sites</last_name>
      <phone>+49 6151 72 5200</phone>
      <email>service@merckgroup.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 3, 2013</lastchanged_date>
  <firstreceived_date>October 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atacicept 75 and 150 mg</keyword>
  <keyword>Placebo</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
